

# Ana Slipicevic

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2284345/publications.pdf>

Version: 2024-02-01

19  
papers

614  
citations

687363

13  
h-index

794594

19  
g-index

19  
all docs

19  
docs citations

19  
times ranked

1160  
citing authors

#	ARTICLE	IF	CITATIONS
1	Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs. <i>Leukemia Research</i> , 2021, 101, 106499.	0.8	7
2	MX2 mediates establishment of interferon response profile, regulates XAF1, and can sensitize melanoma cells to targeted therapy. <i>Cancer Medicine</i> , 2021, 10, 2840-2854.	2.8	6
3	MX 2 is a novel regulator of cell cycle in melanoma cells. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 446-457.	3.3	11
4	Evaluation of <sc>CHK</sc>1 activation in vulvar squamous cell carcinoma and its potential as a therapeutic target in vitro. <i>Cancer Medicine</i> , 2018, 7, 3955-3964.	2.8	8
5	Metabolic reprogramming is associated with flavopiridol resistance in prostate cancer DU145 cells. <i>Scientific Reports</i> , 2017, 7, 5081.	3.3	23
6	MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma. <i>Human Pathology</i> , 2016, 54, 74-81.	2.0	10
7	Cellular localization of <sc>CIP</sc>2A determines its prognostic impact in superficial spreading and nodular melanoma. <i>Cancer Medicine</i> , 2015, 4, 903-913.	2.8	7
8	Expression of CDK1Tyr15, pCDK1Thr161, Cyclin B1 (Total) and pCyclin B1Ser126 in Vulvar Squamous Cell Carcinoma and Their Relations with Clinicopathological Features and Prognosis. <i>PLoS ONE</i> , 2015, 10, e0121398.	2.5	15
9	KIT in Melanoma: Many Shades of Gray. <i>Journal of Investigative Dermatology</i> , 2015, 135, 337-338.	0.7	32
10	Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma. <i>BMC Cancer</i> , 2015, 15, 462.	2.6	43
11	Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions. <i>Gynecologic Oncology</i> , 2014, 135, 118-124.	1.4	59
12	Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis. <i>Cancer Biology and Therapy</i> , 2013, 14, 146-154.	3.4	18
13	Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival. <i>BMC Cancer</i> , 2012, 12, 73.	2.6	28
14	High Expression of Wee1 Is Associated with Poor Disease-Free Survival in Malignant Melanoma: Potential for Targeted Therapy. <i>PLoS ONE</i> , 2012, 7, e38254.	2.5	115
15	Biological effects induced by insulin-like growth factor binding protein 3 (IGFBP-3) in malignant melanoma. <i>International Journal of Cancer</i> , 2010, 126, 350-361.	5.1	20
16	Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions. <i>Human Pathology</i> , 2009, 40, 527-537.	2.0	23
17	The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells. <i>BMC Cancer</i> , 2008, 8, 276.	2.6	66
18	Expression of Activated Akt and PTEN in Malignant Melanomas. <i>American Journal of Clinical Pathology</i> , 2005, 124, 528-536.	0.7	93

#	ARTICLE	IF	CITATIONS
19	Phorbol ester phorbol-12-myristate-13-acetate promotes anchorage-independent growth and survival of melanomas through MEK-independent activation of ERK1/2. <i>Biochemical and Biophysical Research Communications</i> , 2005, 329, 266-274.	2.1	30